Cantor Fitzgerald Issues Positive Estimate for BBIO Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of BridgeBio Pharma in a research report issued on Wednesday, April 30th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings per share of ($3.93) for the year, up from their previous estimate of ($4.62). Cantor Fitzgerald currently has a "Overweight" rating and a $95.00 target price on the stock. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.12. The business had revenue of $36.74 million during the quarter, compared to analysts' expectations of $57.14 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. The company's quarterly revenue was down 44.8% compared to the same quarter last year.

Several other analysts also recently weighed in on BBIO. JPMorgan Chase & Co. lifted their price target on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a research note on Monday, March 24th. Scotiabank raised their target price on shares of BridgeBio Pharma from $52.00 to $55.00 and gave the company a "sector outperform" rating in a research note on Wednesday, April 30th. UBS Group upped their target price on BridgeBio Pharma from $65.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday, April 30th. Citigroup raised their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Finally, Redburn Atlantic began coverage on shares of BridgeBio Pharma in a research note on Monday, March 31st. They set a "buy" rating and a $50.00 price objective on the stock. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $57.09.

BridgeBio Pharma Trading Down 3.2 %

Shares of BBIO traded down $1.17 during trading hours on Friday, reaching $35.77. 1,721,697 shares of the company traded hands, compared to its average volume of 2,363,416. The firm has a market cap of $6.79 billion, a price-to-earnings ratio of -12.55 and a beta of 1.15. BridgeBio Pharma has a 12-month low of $21.62 and a 12-month high of $39.54. The stock's fifty day moving average price is $34.21 and its 200 day moving average price is $31.04.

Hedge Funds Weigh In On BridgeBio Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in BBIO. Barclays PLC increased its position in shares of BridgeBio Pharma by 31.9% in the 3rd quarter. Barclays PLC now owns 545,008 shares of the company's stock valued at $13,876,000 after purchasing an additional 131,743 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of BridgeBio Pharma by 1.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company's stock valued at $29,155,000 after acquiring an additional 19,978 shares during the last quarter. Avanza Fonder AB acquired a new position in BridgeBio Pharma in the fourth quarter valued at approximately $181,000. Moss Adams Wealth Advisors LLC acquired a new stake in BridgeBio Pharma during the fourth quarter worth approximately $208,000. Finally, Atomi Financial Group Inc. purchased a new stake in shares of BridgeBio Pharma during the 4th quarter worth approximately $392,000. 99.85% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total value of $197,760,000.00. Following the transaction, the insider now directly owns 19,260,971 shares in the company, valued at approximately $634,841,604.16. This represents a 23.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Maricel Apuli sold 1,026 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $38.51, for a total value of $39,511.26. Following the completion of the sale, the chief accounting officer now owns 147,639 shares in the company, valued at $5,685,577.89. This represents a 0.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,410,217 shares of company stock valued at $212,434,332 over the last ninety days. Company insiders own 24.66% of the company's stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.